Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul;91(7):2080-2089.
doi: 10.1002/bcp.70031. Epub 2025 Mar 10.

Exposure-tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

Ida Neldemo  1 , Kamunkhwala Gausi  1 , Céline Sarr  1 , Lena E Friberg  1   2 , Reinhard Sailer  3 , Mehdi Lahmar  3 , Girish Jayadeva  4 , Alejandro Pérez-Pitarch  3   5 , Ulrike Schmid  3 , David Busse  3
Affiliations
Clinical Trial

Exposure-tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

Ida Neldemo et al. Br J Clin Pharmacol. 2025 Jul.

Abstract

Aims: Brigimadlin (BI 907828) is a potent, oral MDM2-p53 antagonist under clinical investigation for the treatment of advanced solid tumours. A brigimadlin exposure-tumour growth inhibition (E-TGI) model was developed to support the recommended phase II dose (RP2D) selection of brigimadlin in future clinical trials.

Methods: Population modelling was applied to analyse longitudinal tumour size (sum of longest diameters, SLD) data of 151 patients from a phase I trial treated with 5-80 mg brigimadlin every third or fourth week (q3w/q4w). The impact of brigimadlin exposure on tumour shrinkage was assessed and the effects of patient- and tumour-related covariates on model parameters were explored. The final E-TGI model was used to simulate the effect of brigimadlin treatment on longitudinal SLD. The probability of dropout from tumour assessments were characterized via logistic regression and included in simulations to allow for realistic predictions of tumour shrinkage over time.

Results: The E-TGI model adequately characterized the observed SLD data over time. Simulations demonstrated a substantially stronger tumour shrinkage with higher dose, based on the identified exposure-response relationship. For patients with the most common tumour (dedifferentiated liposarcoma) and standard body weight (70 kg) and remaining in the study for 1 year, the median relative change from baseline in tumour size was 0.141%, -4.48%, -10.8% and -17.4%, for treatment with 20, 30, 45 and 60 mg brigimadlin q3w doses, respectively.

Conclusions: The developed E-TGI model predicted that higher doses of brigimadlin resulted in a substantially stronger tumour shrinkage. These results contributed to selecting 45 mg brigimadlin q3w dose as RP2D in subsequent clinical trials.

Keywords: brigimadlin (BI 907828); dose selection; exposure–response; model‐informed drug development; population pharmacokinetics; tumour growth inhibition.

PubMed Disclaimer

References

REFERENCES

    1. Peuget S, Zhou X, Selivanova G. Translating p53‐based therapies for cancer into the clinic. Nat Rev Cancer. 2024;24(3):192‐215. doi:10.1038/s41568‐023‐00658‐3
    1. Marei HE, Althani A, Afifi N, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703. doi:10.1186/s12935‐021‐02396‐8
    1. LoRusso P, Yamamoto N, Patel MR, et al. The MDM2‐p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first‐in‐human, dose‐escalation study. Cancer Discov. 2023;13(8):1802‐1813. doi:10.1158/2159‐8290.Cd‐23‐0153
    1. Schöffski P, Lahmar M, Lucarelli A, Maki RG. Brightline‐1: phase ii/iii trial of the MDM2‐p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Future Oncol. 2023;19(9):621‐629. doi:10.2217/fon‐2022–1291
    1. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003‐1010. doi:10.1038/ng.3375

Publication types

Substances

Grants and funding